RxDoctor Payments Data

Michael Brucculeri, MD

Nephrology · Clearwater, FLNPI 1346271145

Payments from drug & device makers

$78,077in general payments, 2019–2025

Across 236 payments — averaging $330.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$42K
  • Otsuka America Pharmaceutical, Inc.$30K
  • Vifor Pharma, Inc.$4K
  • Amgen$335
  • Novartis$212
  • AstraZeneca$195
  • plus $832 from 18 others

What the payments were for

  • Consulting fees$2,5003%
  • Speaking & faculty fees$67,02386%
  • Travel & lodging$3,5325%
  • Food & beverage$4,9976%
  • Education$250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$78,077 in reported general payments places this provider in the 85th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$661,785
Medicare patients
1,328
Services billed
6,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tolvaptan68$463,488
VelphoroSucroferric Oxyhydroxide89$252,258
FarxigaDapagliflozin Propanediol102$135,868
Cinacalcet Hcl381$96,372
XphozahTenapanor Hcl23$59,982
JardianceEmpagliflozin41$48,477
VeltassaPatiromer Calcium Sorbitex22$42,200
LokelmaSodium Zirconium Cyclosilicate33$33,726
Demeclocycline Hcl64$29,154
Calcitriol1,298$28,191
EliquisApixaban23$24,571
Sevelamer Carbonate128$22,034
Lanthanum Carbonate18$19,888
Potassium Citrate ErPotassium Citrate151$17,925
KerendiaFinerenone25$17,250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka Pharmaceutical Development & Commercialization, Inc.Tolvaptan$26$463,48868 claims
Fresenius USA Marketing, Inc.Velphoro$42,093$252,25889 claims
AstraZenecaFarxiga, Lokelma$195$169,594135 claims
BayerKerendia$78$17,25025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 756 nephrology providers in Florida.

Other nephrology in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →